INTRODUCTION: Tadalafil distinguishes itself from other available phosphodiesterase type 5 (PDE-5) inhibitors by its half-life of ∼ 17.5 h, which results in erectile responsiveness for up to 36 h after a single dose.
Most clinical experience has been reported with on-demand use of PDE-5 inhibitors, but several studies have been able to demonstrate that tadalafil, given once-daily in low doses, is both highly effective and well tolerated.
AREAS COVERED: This paper reviews the current evidence for efficacy and safety of tadalafil, as well as the rationale for offering low-dose tadalafil once-daily to patients with erectile dysfunction as an alternative to on-demand treatment.
EXPERT OPINION: Tadalafil once-daily provides efficacy comparable to on-demand dosing regimens with PDE-5 inhibitors, is well tolerated and allows patients and their partners to disconnect the administration of medication from sexual activity, thereby enabling them to return to the sex-life they had before the onset of erectile dysfunction.
Written by:
Porst H, Hell-Momeni K, Büttner H. Are you the author?
Urology and Andrology Center, Neuer Jungfernstieg 6a, 20354 Hamburg, Germany.
Reference: Expert Opin Pharmacother. 2012 Jul;13(10):1481-94.
doi: 10.1517/14656566.2012.693162
PubMed Abstract
PMID: 22725705
UroToday.com Erectile Dysfunction Section
